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Congenital adrenal hyperplasia consists of a heterogenous group 
of inherited disorders due to enzymatic defects in the biosynthetic 
pathway of cortisol and/or aldosterone. This results in glucocorti-
coid deficiency, mineralocorticoid deficiency and androgen excess. 
95% of CAH cases are due to 21-hydroxylase deficiency. Clinical 
forms range from the severe, classical CAH associated with complete 
loss of enzyme function, to milder, non-classical forms (NCAH). 
Androgen excess affects the pilosebaceous unit, causing cutaneous 
manifestations such as acne, androgenetic alopecia and hirsutism. 
Clinical differential diagnosis between NCAH and polycystic ovary 
syndrome may be difficult. In this review, the evaluation of patients 
with suspected CAH, the clinical presentation of CAH forms, with 
emphasis on the cutaneous manifestations of the disease and avail-
able treatment options, will be discussed.
Introduction
The  human  adrenal  glands  synthesize  three  main  classes  of 
hormones,  namely  mineralocorticoids,  glucocorticoids  and  sex 
steroids, through a series of enzymatic steps from the cholesterol 
precursor molecule. In particular, the human adrenal cortex consists 
of three zones, the zona glomerulosa where aldosterone is produced, 
the zona fasciculata where glucocorticoids are produced and the zona 
reticularis where adrenal androgens are produced.1
The earliest case of congenital adrenal hyperplasia (CAH) was 
reported in 1865 by the Neapolitan anatomist De Crecchio.2 CAH 
is defined as a group of inherited autosomal recessive disorders which 
result from an enzyme defect in the biosynthetic pathway of cortisol 
and/or aldosterone.3
The anterior pituitary regulates adrenal steroidogenesis via adre-
nocorticotropic hormone (ACTH). The circulating level of plasma 
cortisol is a key player in the hypothalamic-pituitary-adrenal feed-
back system and exerts a negative feedback effect on the secretion 
of ACTH. So, in case of a decrease in cortisol secretion, increased 
ACTH secretion will follow.4 In most forms of CAH, an enzyme 
defect  blocks  cortisol  synthesis,  thus  impairing  cortisol-mediated 
negative  feedback  control  of  ACTH  secretion.  Oversecretion  of 
ACTH ensues, which results in overstimulation of the adrenals and 
causes their hyperplasia.3 Also, ACTH oversecretion stimulates exces-
sive synthesis of the adrenal products of those pathways unimpaired 
by an enzyme deficiency and causes an accumulation of precursor 
molecules in pathways blocked by an enzyme deficiency.4
95% of CAH cases are due to 21-hydroxylase (21OH) deficiency, 
caused by mutations in the 21-hydroxylase gene (CYP21A2). CAH 
due  to  21-hydroxylase  deficiency  (21OHD  CAH)  is  one  of  the 
most commonly known autosomal recessive disorders in humans.3 
21-OH is a cytochrome P450 that is required for the conversion of 
17-hydroxyprogesterone  to  11-deoxycortisol,  and  when  deficient 
results in impaired synthesis of cortisol. Also, 21OH is required for 
mineralocorticoid production and when deficient, results in impaired 
synthesis of aldosterone. On the other hand, it does not participate in 
the pathway of androgen production (Fig. 1). Consequently, the loss 
of the cortisol-mediated negative feedback control of ACTH secre-
tion results in oversecretion of ACTH and overproduction of adrenal 
androgens.4 Different CYP21 mutations result in varying degrees of 
impaired 21-OH activity and cause a spectrum of disease expression.5
The clinical forms of 21OHD CAH are typically classified as clas-
sical, the severe form (CAH), or non-classic (21OHD-NCAH), the 
mild or late-onset form. Sometimes congenital adrenal hyperplasia 
may remain asymptomatic (cryptic form). Classic congenital adrenal 
hyperplasia is subclassified as salt-wasting (SW) or simple-virilizing 
(SV) forms, depending on the presence of aldosterone deficiency 
(Fig. 2).3
Classical and Nonclassical 21-Hydroxylase Deficiency
Epidemiology. Classical congenital adrenal hyperplasia occurs in 
approximately 1/15.000 births, while 21OH-NCAH is much more 
frequent and occurs in approximately 1% of the general population, 
with an incidence of 1:500 to 1:1,000 in various Caucasian popula-
tions.6 Some ethnic groups are at higher risk, such as Ashkenazi Jews 
(prevalence: one in 27), Hispanics (one in 40) and Slavics (one in 
50).7-9 NCAH has been found in less than 5% of hyperandrogenic 
women in the general population.9
Genetics. The most frequent CAH variant, accounting for 95% 
of all affected patients, is 21-hydroxyase deficiency, caused by dele-
tions and deleterious mutations in the active 21-hydroxylase gene 
(CYP21). The CYP21 gene was decoded in 1986 and the molecular 
genetic mutations specific for the nonclassical from of 21 OHD have 
later been deciphered.10-13 The CYP21 gene is located on chromo-
some 6p21.3, forming tandemly repeated units with the pseudogene, 
CYP21P. The CYP21 and CYP21P genes present 98% homology in 
their nucleotide coding sequence.14,15
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with a variety of hyperandrogenic symptoms presenting either in 
childhood  (precocious  puberty),  or  sometimes  later  in  adulthood 
(acne, infertility).20,22
Precocious  puberty  may  present  in  childhood,  with  advanced 
bone age, accelerated growth and premature development of pubic 
or axillary hair. Nevertheless, growth is eventually arrested because of 
early epiphyseal fusion which compromises final height (tall children, 
short adults).23 Also, a high incidence of molecular defects of CYP21 
gene has been shown in a series of Greek children with premature 
adrenarche.24
Androgenic alopecia may be the sole symptom in young women 
with NCAH.25
Moreover,  women  with  21OHD-NCAH  may  present  with 
hirsutism which is the most common symptom. The prevalence of 
hirsutism may increase with age, highlighting the progressive nature 
The clinical spectrum ranges from classical 
congenital adrenal hyperplasia associated with 
complete loss of enzyme function with presen-
tation  in  the  neonatal  period,  to  milder  or 
non-classical forms presenting in adolescence 
or adulthood. Mutations producing enzymes 
retaining  20  to  60%  of  normal  activity  are 
associated  with  NCAH,  while  more  serious 
mutations  resulting  in  totally  ablate  enzyme 
activity or 1–2% of normal activity, are associ-
ated with classic disease.14
DNA-based  prenatal  diagnosis  and  treat-
ment of 21OH-CAH has been used for over 
15 years and is indicated in case of a family 
history of CAH, making CAH the first inborn 
metabolic disorder to be successfully treated 
prenatally.4,16  Also,  neonatal  screening  for 
CAH is possible.17
Clinical manifestations of classical CAH. 
Clinical manifestations in classical CAH are 
due to glucocorticoid deficiency, mineralocor-
ticoid deficiency and androgen excess.
Also,  the  deficiency  of  cortisol  secretion 
is associated with abnormalities in the secre-
tion  of  other  pituitary  hormones,  namely 
growth  hormone  (GH)  and  thyroid  stimu-
lating hormone (TSH).18,19
Both the SV and the SW forms of 21OH 
CAH are characterized by prenatal virilization 
of the female genitalia and postnatal viriliza-
tion of both boys and girls, due to excessive 
adrenal androgen secretion.4 The SW form of 
CAH, without treatment will lead to death, 
due to electrolyte abnormalities and vascular 
collapse.5,20
Postnatally,  in  untreated  boys  and  girls, 
androgen  excess  results  in  rapid  growth, 
advanced  epiphyseal  maturation,  and  ulti-
mately,  early  epiphyseal  closure  and  short 
stature  (tall  children,  short  adults).  Also, 
untreated patients present early appearance of 
facial, axillary and pubic hair and acne.5
Fertility in female CAH patients is reduced, due to surgical (inad-
equate vaginal introitus), endocrinologic (elevated follicular phase 
progesterone concentrations) or psychological reasons. However, the 
prospects for achieving fertility have improved markedly and young 
women can be reassured that it is often possible.21
In  male  patients,  suppression  of  gonadotrophins  by  adrenal 
testosterone and adrenal ‘rests’ stimulated by ACTH lead to infer-
tility, as a result of poor compliance with glucocorticoid treatment. 
Male infertility is potentially reversible with increased glucocorticoid 
suppression.3,5,6
Clinical  manifestations  of  non-classical  CAH.  NCAH  is  a 
widely  underdiagnosed  disorder  in  children  and  adults;  a  few 
NCAH  cases  are  detected  by  newborn-screening  programs  but 
most  are  missed  because  of  the  relatively  low  baseline  levels  of 
17-hydroxyprogesterone  (17OHPG).  NCAH  may  be  associated 
Figure 1. Simplified scheme of the role of 21-hydroxylase in the adrenal steroidogenesis pathway.
Figure 2. Clinical forms of CAH.
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and isotretinoin has been associated with NCAH due to 21-OH 
deficiency.41-43 Most of the men with NCAH are fertile (Table 1).5
In NCAH, cortisol synthesis during stress is not impaired and 
there is no risk of adrenal insufficiency.5
Evaluation of the Patient with Suspected CAH
Biochemical  diagnosis  of  CAH  relies  on  the  determination  of 
17-OH PG, the immediate substrate for 21-OH. A basal 17-OH PG 
level >6.1 nmol/L (>2 ng/mL or 200 ng/dl) can serve for screening 
for NCAH.5
The ACTH stimulation test is the best screening test for evalu-
ating  adrenal  gland  function,  and  it  is  valuable  in  cases  of  mild 
forms of congenital adrenal hyperplasia with normal basal adrenal 
steroids.44 It has been used for the biochemical diagnosis of NCAH 
due to other enzyme deficiencies.45 The test should be performed 
in the early follicular phase (day 3–7 of the menstrual cycle). Blood 
samples are obtained before (0 min) and 60 min following intrave-
nous injection of Tetracosactid, 25 IU (hormonally active ACTH 
fragment,  Synachten,  Novartis,  Nürnerg,  Germany).  Basal  and 
stimulated  17-OH  PG  levels  are  determined  and  the  possibility 
of CAH is considered if basal 17-OH PG levels are elevated and/
or ACTH-stimulated 17-OH PG is more than 260 ng/dL (7.87 
nmol/L) above the basal level.44,46 Furthermore, the diagnosis of 
21-OH deficient NCAH is established by the response of 17-OH 
progesterone to adrenocortical stimulation with levels >30.3 nmol/L 
(>10 ng/mL).5,26 Further investigations for CAH are summarized in 
Table 2.5
Borderline biochemical data may make diagnosis of NCAH chal-
lenging.20 So, NCAH should be differentiated from other disorders, 
including PCOS, Cushing’s syndrome, hyperprolactinemia, thyroid 
dysfunction  and  androgen-secreting  tumors.9  In  women,  NCAH 
presenting  with  skin  manifestations  of  androgen  excess  such  as 
acne, androgenetic alopeica or hirsutism, should be differentiated 
from polycystic ovary syndrome; oligomenorrhea or amenorrhea are 
uncommon in NCAH.47 Polycystic ovary syndrome has been defined, 
based  on  an  international  agreement  (The  Rotterdam  Consensus 
Group in 2003), by the presence of at least two of the following: (1) 
oligomenorrhea  or  amenorrhea,  (2)  clinical  hyperandrogenism  or 
serum androgen excess, (3) polycystic ovaries by a pelvic ultrasound 
(ovarian volume ≥10 cm3, multiple follicle (≥12) distributed periph-
erally, stroma increased).48 In patients with hirsutism and suspected 
NCAH, such as those with a positive family history of CAH or in 
high-risk ethnic groups (Ashkenazi Jews, Hispanics, Slavics), an early 
morning, follicular phase level of 17-OHPG should be measured to 
facilitate diagnosis.9
Molecular  diagnosis.  The  utility  of  genotype  analysis  of  the 
21-OH  gene  has  been  proposed  in  hyperandrogenic  women 
presenting  symptoms  ranging  from  hirsutism,  acne  and  amenor-
rhea, to decreased fertility, in order to distinguish heterozygous from 
wild-type individuals and to characterize biochemically borderline 
individuals.20 Nevertheless, in clinical practice, molecular biology is 
not routinely available.
Management of the CAH Patient
General  considerations.  Current  treatment  of  classical  CAH 
is  intended  to  reduce  excessive  ACTH  and  the  consequent 
increase  in  androgen  production,  by  substituting  for  cortisol   
of NCAH.26 NCAH was reported in 14% of young women with 
hirsutism  and  oligomenorrhea  in  a  retrospective  study,27  and  in 
1.2–30%  of  hirsute,  oligomenorrheic  women  in  other  published 
series.28-32
Furthermore, studies in female patients show that NCAH may 
present with menstrual irregularities, obesity, short stature, infertility 
or  subfertility  and  skin  disorders,  including  hirsutism,  seborrhea 
and/or acne in the peripubertal period. These clinical characteristics 
of NCAH do not differ from those in female patients with poly-
cystic ovary syndrome (PCOS), or hyperinsulinemia.23,33,34 Insulin 
insensitivity in females with NCAH has been described, but it has 
not been established whether an association with acne exists in these 
patients.35 Nevertheless, insulin resistance results in compensatory 
hyperinsulinemia which, in turn, may increase the responsiveness of 
the pilosebaceous unit to androgens.36
Some women with NCAH present with PCOS. In these cases, 
either  the  cyclicity  of  gonadotropin  release  is  disrupted,  or  the 
ovary is directly affected by adrenal androgen excess. As a result, 
ovarian  cysts  are  formed,  which  begin  to  autonomously  produce 
androgens.4,23 The frequency of NCAH in PCOS has been reported 
in  some  studies.  A  prospective  study  of  107  Greek  women  with 
hirsutism and PCOS, showed that 10% were affected by NCAH.34 
A  prevalence  of  9.52%  and  33%  have  been  reported  in  women 
suffering from hirsutism and PCOS in Turkey.37,38 In a study of 
Spanish women with hirsutism, irregular menses, acne or androgenic 
alopecia, NCAH was found in 2.2%, based on biochemical evidence 
or molecular genotype analysis.39
Male patients with NCAH may be asymptomatic or present with 
acne or infertility.40 Severe cystic acne refractory to oral antibiotics 
Table 1    Cutaneous manifestations of CAH forms due to 
21-hydroxylase deficiency
Classic form  Non classic form
•  Virilization: female pseudohermaphroditism  •  Acne
•  Early appearance of facial,   •  Hirsutism
     axillary and pubic hair
•  Acne  •  Androgenic alopecia
•  Hirsutism  •  PCOS
Table 2    Investigations for suspected congenital adrenal 
hyperplasia in patients with acne
•  Thorough medical history: age of pubarche, infertility, acne, use of         
     androgenic medications
•  Physical examination
•  Serum luteinizing hormone (LH), follicle-stimulating hormone (FSH)
•  Testosterone, DHEA-S, androstenedione
•  Basal plasma 17-OH progesterone (8.00 am): >15 nmol/l (>2 ng/ml)
•  ACTH-stimulation test
•  Pelvic ultrasonography: to detect polycystic ovaries
•  Computed tomography: for the exclusion of adrenal tumor
•  Molecular gene analysisCongenital adrenal hyperplasia
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(with oral   glucocorticoids, including prednisolone, hydrocortisone 
or  dexamethasone)  and,  when  necessary,  aldosterone  deficiency 
(with fludrocortisone).3 During childhood, the main aims of medical 
treatment of 21OH CAH are to prevent salt loss and virilization, to 
achieve normal stature and to undergo normal puberty. In adult-
hood, the aims of medical treatment are to ensure normal fertility 
and to avoid the long-term consequences of glucocorticoid use.3
Treatment of non-classical late onset form depends on the main 
problem  of  the  patient,  such  as  acne,  hirsutism  or  androgenetic 
alopecia.40
Management of cutaneous manifestations of CAH. Adolescents 
or adult CAH patients represent the group that may need dermato-
logic attention, as acne and hirsutism, the main skin manifestations 
of CAH, usually develop during adolescence.
For the treatment of acne associated with NCAH, oral gluco-
corticoids are administered in order to counteract adrenal androgen 
production.44  Low-dose  prednisone  (2.5–5  mg/day)  or  low-dose 
dexamethasone  (0.25–0.75  mg)  can  be  given  orally  at  bedtime, 
although the latter incurs a higher risk of adrenal suppression.44,49 
Oral methylprednisolone (initial dose of 1 mg/kg/day) in combi-
nation  with  oral  isotretinoin  was  a  successful  treatment  for  acne 
fulminans in a boy with NCAH.46 In order to ensure that gluco-
corticoids are efficacious, the serum DHEAS level can be monitored 
for a decrease or normalization. To check for adrenal suppression, an 
ACTH stimulation test should be performed two to three months 
after initiation of therapy. This involves assessing the plasma cortisol 
level 30 minutes following an injection of 250 μg/m2 ACTH. A raise 
in plasma cortisol by appropriate amounts (>16 μg/dL) indicates that 
the adrenal gland is not suppressed.50
The risk of osteoporosis associated with long-term administration 
of glucocorticoids is even more prominent in teenagers whose bone 
development  is  still  ongoing. Therefore,  low-dose  glucocorticoids 
should not be taken for a time period longer than six months.44
Treatment  of  hirsutism  is  reviewed  elsewhere,  and  includes 
physical  methods  to  remove  excess  hair  and/or  anti-androgens 
(spironolactone, cyproterone acetate, drospirenone), or finasteride.51 
Cyproterone acetate was found better than hydrocortisone in the 
treatment of hirsutism in women with NCAH.52
Conclusions
CAH is generally considered to be an endocrine disease. However, 
the hyperandrogenism associated with CAH (classical or non-clas-
sical form) can have a major impact on the skin of affected patients.53 
One  should  keep  in  mind  that  although  hyperandrogenism  is  a 
major cause of concern for women, it may also affect men, with acne 
being the sole presenting symptom. Dermatologists should be able 
to evaluate for CAH forms and provide therapeutic options for acne 
and hisrutism associated with CAH. In order to provide the CAH 
patient with optimal care, a multidisciplinary approach comprising 
endocrinologists, gynecologists, plastic surgeons, as well as derma-
tologists, is therefore essential.
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